Alcon Inc.

What does Alcon own?
Alcon owns a portfolio of eye care brands across two business segments. In Surgical, the company owns intraocular lens brands including Clareon, PanOptix, and AcrySof, surgical equipment brands, and consumable products. In Vision Care, Alcon owns contact lens brands including TOTAL30, PRECISION7, DAILIES, and Air Optix, and ocular health brands including Systane and Tryptyr. The company also owns Aerie Pharmaceuticals, which produces glaucoma treatments.

Is Alcon publicly traded?
Yes, Alcon Inc. trades on the New York Stock Exchange under ticker ALC and on the SIX Swiss Exchange under the same ticker. The company was spun off from Novartis in April 2019 and began trading as an independent company. Alcon is incorporated in Switzerland and headquartered in Geneva.

Who founded Alcon?
Alcon was founded in 1945 by Robert Conron and William Conron in Fort Worth, Texas. The company's name is derived from the first syllables of "Alex" and "Conron." The founders initially focused on manufacturing ophthalmic products, including sterile ophthalmic solutions and instruments for eye surgery. Alcon was later acquired by Nestle in 1977 and then by Novartis in 2010 before being spun off as an independent company in 2019.

Where is Alcon headquartered?
Alcon is headquartered in Geneva, Switzerland. The company was incorporated in Switzerland ahead of its 2019 spin-off from Novartis. Alcon maintains significant operations in Fort Worth, Texas, where it was originally founded, along with manufacturing facilities in Switzerland, the United States, Mexico, Japan, China, India, and Belgium.

How many brands does Alcon own?
Alcon owns multiple eye care brands across its Surgical and Vision Care segments. Key brands include TOTAL30, PRECISION7, DAILIES, Air Optix, Systane, Tryptyr, PanOptix, Clareon, and Aerie Pharmaceuticals products. The company's portfolio is focused exclusively on eye care, with products spanning contact lenses, ocular health treatments, intraocular lenses, and surgical equipment.

Who owns Alcon?
Alcon is a publicly traded corporation owned by its shareholders. Major institutional holders include Vanguard Group, BlackRock, and other large asset managers. Novartis distributed all of its Alcon shares to Novartis shareholders in the April 2019 spin-off, retaining no ownership stake. No single shareholder holds a controlling interest in the company.

What is Alcon's revenue?
In FY2025, Alcon reported net sales of $10.3 billion, up 5% as reported and 4% on a constant currency basis. Diluted earnings per share were $1.98, and core diluted EPS was $3.07. The company generated $2.3 billion in cash from operating activities and $1.7 billion in free cash flow. In Q1 2026, net sales were $2.69 billion, up 10% as reported.

Has Alcon made any recent acquisitions?
Yes, Alcon has been active in acquisitions. In 2025, the company acquired a majority interest in Aurion Biotech for approximately $522 million, completed the acquisition of LumiThera for $124 million, and acquired approximately 91.2% of Cylite Pty Ltd. In March 2025, Alcon agreed to acquire LENSAR for up to $430 million, but terminated the agreement in March 2026. In 2022, Alcon acquired Aerie Pharmaceuticals for approximately $770 million.

Alcon was founded in 1945 by Robert Conron and William Conron in Fort Worth, Texas. The company's name is derived from the first syllables of "Alex" and "Conron." The founders initially focused on manufacturing ophthalmic products, including sterile ophthalmic solutions and instruments for eye surgery.

In 1947, Alcon introduced its first proprietary product, a zinc sulfate ophthalmic solution. The company grew through the 1950s and 1960s by expanding its product line and distribution network. In 1977, Alcon was acquired by Nestle for approximately $280 million, becoming a subsidiary of the Swiss food and beverage conglomerate.

Under Nestle's ownership, Alcon expanded its portfolio through acquisitions and internal development. The company entered the contact lens market in the 1980s and expanded its surgical equipment business. In 1989, Alcon acquired CooperVision's surgical business, strengthening its position in ophthalmic surgical devices.

In 2002, Nestle sold approximately 25% of Alcon through an IPO on the New York Stock Exchange. Novartis acquired Nestle's remaining stake in Alcon in two stages, purchasing approximately 25% in 2008 for $11 billion and the remaining 52% in 2010 for $28.1 billion, bringing its total ownership to 100%. The total acquisition cost Novartis approximately $51 billion, making it one of the largest healthcare acquisitions at the time.

Under Novartis's ownership, Alcon operated as a division of the pharmaceutical giant. The business grew through acquisitions, including the 2011 acquisition of Ista Pharmaceuticals for approximately $230 million and the 2014 acquisition of WaveTec Vision for an undisclosed sum. However, Alcon's growth slowed relative to Novartis's pharmaceutical business, and in 2018, Novartis announced its intention to spin off Alcon as an independent company.

The spin-off was completed on April 9, 2019, with Alcon shares distributed to Novartis shareholders. The new independent company began trading on the SIX Swiss Exchange and the NYSE under the ticker ALC. At the time of the spin-off, Alcon had approximately $7 billion in annual revenue and 25,000 employees.

Following the spin-off, Alcon pursued a strategy of portfolio expansion through acquisitions and new product launches. In 2020, the company acquired Dailies Total1 and expanded its contact lens portfolio. In 2022, Alcon acquired Aerie Pharmaceuticals for approximately $770 million, adding glaucoma treatments to its ophthalmic pharmaceutical portfolio.

In 2025, Alcon made several acquisitions to expand its portfolio. In January 2025, the company acquired approximately 91.2% of Cylite Pty Ltd, an Australian company developing ophthalmic diagnostic devices. In March 2025, Alcon acquired a majority interest in Aurion Biotech for approximately $522 million, gaining a cell therapy candidate for corneal conditions. Also in 2025, Alcon completed the acquisition of LumiThera for $124 million, adding the Valeda photobiomodulation device for dry age-related macular degeneration.

In March 2025, Alcon entered into a definitive agreement to acquire LENSAR, Inc. for up to approximately $430 million. However, on March 16, 2026, Alcon terminated the merger agreement, abandoning the acquisition.

In Q1 2026, Alcon launched 10 new products, including Clareon TruPlus IOL, PanOptix Pro, Tryptyr for dry eye, and PRECISION7 contact lenses. The company reported Q1 2026 net sales of $2.69 billion, up 10% as reported. Alcon's Q2 2026 earnings call is scheduled for August 11, 2026.

Alcon publishes an annual sustainability report detailing its environmental, social, and governance performance. The company's sustainability strategy focuses on three areas: access to eye care, environmental responsibility, and ethical business practices.

In environmental responsibility, Alcon has set targets for reducing greenhouse gas emissions and water usage in its manufacturing operations. The company reports its environmental metrics in its annual sustainability report. Alcon's manufacturing facilities in Switzerland, the United States, and other countries have implemented energy efficiency programs and waste reduction initiatives.

In access to eye care, Alcon operates the Alcon Foundation, which supports programs providing eye care in underserved communities. The foundation partners with organizations including Orbis International and the Fred Hollows Foundation to deliver eye care services in developing countries. Alcon also donates surgical equipment and supplies to training programs and charitable clinics.

In ethical business practices, Alcon maintains a code of conduct and compliance program covering its global operations. The company is subject to medical device regulations in all markets where it operates, including FDA regulations in the United States, CE marking requirements in Europe, and equivalent regulations in other countries.

Alcon's sustainability reporting is based on the Global Reporting Initiative (GRI) standards. The company has not committed to a net-zero target or science-based emissions reduction targets as of 2026.

• Fortune World's Most Admired Companies (2025): Alcon was included in Fortune's annual ranking of the most admired companies in the medical equipment industry.
• Forbes Global 2000 (2025): Alcon was ranked among the world's largest public companies by revenue, profit, assets, and market value.
• Newsweek World's Most Trustworthy Companies (2025): Alcon was recognized for trustworthiness based on an independent survey of over 70,000 participants.

Alcon has faced regulatory scrutiny related to its medical device products. As a manufacturer of surgical equipment and contact lenses, the company is subject to regulation by the FDA in the United States, the European Medicines Agency in Europe, and equivalent regulatory bodies in other markets.

In 2025, Alcon entered into a definitive agreement to acquire LENSAR, Inc. for up to approximately $430 million. The acquisition was intended to expand Alcon's cataract surgery laser portfolio. However, on March 16, 2026, Alcon terminated the merger agreement, abandoning the acquisition. The termination was announced without detailed explanation, though it may have been related to regulatory review or strategic reassessment.

Alcon has faced product recalls and safety communications related to its contact lens and surgical products. These recalls have been managed through standard regulatory channels, with Alcon issuing notifications to eye care professionals and coordinating with regulatory bodies. No major safety scandal or regulatory enforcement action has been publicly documented in recent years.

The company's acquisition strategy has drawn some scrutiny. The acquisition of a majority interest in Aurion Biotech for approximately $522 million in March 2025 represented a significant investment in cell therapy, a relatively new area for Alcon. The acquisition of LumiThera for $124 million expanded Alcon's portfolio into photobiomodulation treatment. These acquisitions are part of Alcon's strategy to expand beyond its core surgical and vision care businesses into ophthalmic pharmaceuticals and biopharmaceutical applications.